ABSTRACT
Limited evidence is available to guide treatment of coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A hyperinflammatory state mediated by interleukin-6 (IL-6) has been proposed as a driver of severe disease. Use of the IL-6 receptor inhibitor tocilizumab for severe COVID-19 was first reported in China, where a case series described marked improvements in inflammatory markers, fever, oxygen requirement, and outcomes following its administration. Here, we provide the first description of a tocilizumab-treated cohort of patients with COVID-19 in the United States. We describe 11 patients from a single academic medical center, nine (82%) of whom were critically ill requiring mechanical ventilation in an intensive care unit at the time of tocilizumab administration. C-reactive protein levels decreased in all patients following treatment (median 211.6 pre- vs. 19.7 mg/L 5 days post-tocilizumab [p = 0.001]). When IL-6 levels were obtained before and after therapy, wide variation was seen in baseline levels; post-dose IL-6 concentrations were consistently increased. In contrast to prior reports, we did not observe significant clinical improvement in temperature or oxygen requirements in most patients. Two patients were discharged (18%), five remained in critical condition in the intensive care unit (46%), one was weaned off the ventilator to room air (9%), and three died (27%). Our findings suggest that tocilizumab should be used with caution in severe and critically ill patients and highlight the need for data from randomized controlled trials to determine its efficacy in the treatment of COVID-19.
Competing Interest Statement
JBP reports research support outside the submitted work from Gilead Sciences and the World Health Organization, and non-financial support from Abbott Laboratories. CLG has received research support outside the submitted work from Viiv Healthcare and Gilead Sciences. SSC reports research support outside of the submitted work from Biomarck Pharmaceuticals.
Funding Statement
The authors report no designated funding for the project. CAR and CEM receive training support from the University of North Carolina at Chapel Hill Medical Scientist Training Program. CAR additionally receives training support from the National Institutes of Health MD/PhD Partnership Program.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
1
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos